Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.
|First Received Date||May 24, 2016|
|Last Changed Date||November 13, 2018|
|Start Date||October 7, 2016|
|Anticipated Primary Completion Date||May 2019|
|Primary Outcome Measures||
Progression free survival measured as time from randomization to first observation of objective disease relapse or progression [Time Frame: 32 months]
|Secondary Outcome Measures||
Number and severity of adverse events [Time Frame: 32 months]
Overall Survival [Time Frame: 32 months]
Quality of Life using EORTC QLQ-C30 [Time Frame: 32 months]
Response rate compared using Fisher's exact test [Time Frame: 32 months]
|Study Arms / Comparison Groups||3 / 0|
The purpose of this study is to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of life
|Ages||18 Years - N/A|
|Accepts Healthy Volunteers||No|
- Patients must have histologically confirmed malignant pleural mesothelioma. Patients must be eligible to receive standard chemotherapy with pemetrexed and cisplatin and have no contraindications to standard chemotherapy.
- Patients must have unresectable advanced and/or metastatic disease, incurable by standard therapies.
- All patients must have a tumour block from their primary or metastatic tumour available and consent to release the block/recently cut slides for correlative analyses (See Section 11.0) and the centre/pathologist must have agreed to the submission of the specimen(s).
- Presence of radiologically documented disease. At least one site of disease must be unidimensionally measurable as follows:
- CT scan (with slice thickness of ≤ 5 mm): ≥ 10 mm --> longest diameter
- Physical exam (using calipers): ≥ 10 mm
- Lymph nodes by CT scan ≥ 15 mm --> measured in short axis
- All radiology studies must be performed within 21 days prior to registration (exception: within 28 days if negative).
- Age ≥ 18 years.
- ECOG performance status 0 or 1.
- Patients must not have received prior chemotherapy for any stage of advanced/metastatic disease.
- Patients who received previous (neo)adjuvant cisplatin-based systemic chemotherapy must have received the last dose of chemotherapy at least 12 months before registration.
Other Anti-Cancer Therapy:
- Patients may not have received targeted small molecule therapy, immunotherapies and viral therapies, biologic therapies and angiogenesis inhibitors for advanced/metastatic disease, or any prior immunotherapy for any stage of disease.
- Patients may have had prior radiation therapy. A minimum of 28 days must have elapsed between the end of radiotherapy and registration onto the study. Radiation must have involved < 30% of functioning bone marrow and there must be measurable disease outside the previously irradiated area (patients whose sole site of disease is in a previously irradiated area are ineligible UNLESS there is evidence of progression, or new lesions have been documented, in the irradiated field). (Exceptions may be made however, for low dose, palliative radiotherapy - please call the CCTG at 613-533-6430 PRIOR to registration if questions arise about the interpretation of this criterion). Patients must have recovered from any acute toxic effects from radiation prior to registration.
- Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration and that wound healing has occurred.
- Lab Requirements:
- Absolute neutrophils ≥ 1.5 x 10^9/L
- Platelets ≥ 100 x 10^9/L
- Hemoglobin ≥ 90 g/L
- Bilirubin ≤ 1.5 x ULN (upper limit of normal)
- AST and ALT ≤ 2.5 x ULN
- Serum creatinine < 1.25 x ULN or Creatinine clearance ≥ 50 mL/min
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.
- Patients must be accessible for treatment, response assessment and follow-up. Patients registered on this trial must be treated and followed at the participating centre.
- In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient randomization.
- Women/men of childbearing potential must have agreed to use two highly effective contraceptive methods during the study and for six months after discontinuation.
- Patient must be able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at doses more than 10 mg prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has active autoimmune disease that has required systemic treatment in the past 3 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Must not have received a live vaccine within 30 days of planned start of study therapy.
- Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, should have a LVEF ≥ 50%.
- Patients with a history of other malignancies requiring concurrent anticancer therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or any of the other chemotherapy agents.
- Patients receiving concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
- Patients with serious illness or medical condition that would not permit the patient to be managed according to the protocol including, but not limited to:
- History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
- Active infection requiring systemic therapy; (including any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) [note: testing in asymptomatic patients is not required] or tuberculosis).
- Known history of, or any evidence of active, non-infectious pneumonitis.
- Any other medical conditions that might be aggravated by treatment.
- Serious or non-healing wound, ulcer, or bone fracture.
- Patients with evidence of interstitial lung disease.
- Pregnant or lactating women. (N.B.: All women of childbearing potential must have a negative pregnancy test within 72 hours prior to registration).
|Sponsor||Canadian Cancer Trials Group|
|Verification Date||April 2018|